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Objectives. This study was designed to evaluate the effect of 
pravastatin on progression of coronary atherosclerosis and isch- 
emic events in patients with coronary artery disease and mild to 
moderate hyperlipidemia. 
Background. Few clinical trial data support the use of lipid- 
lowering therapy in patients with coronary artery disease and 
mild to moderate elevations in cholesterol levels. 
Methods. Four hundred eight patients (mean age 57 years) with 
coronary artery disease and low density lipoprotein (LDL) cho- 
lesterol _>130 mg/dl (3.36 mmol/liter) but <190 mg/dl ([4.91 
retool/liter]) despite diet were randomized in a 3-year study to 
receive pravastatin or placebo. Atherosclerosis progression was 
evaluated by quantitative coronary arteriography. 
Results. Baseline mean LDL cholesterol was 164 mg/dl (4.24 
mmol/liter). Pravastatin decreased total and LDL cholesterol and 
triglyceride levels by 19%, 28% and 8%, respectively, and in- 
creased high density lipoprotein cholesterol by 7% (p _< 0.001 vs. 
placebo for all lipid variables). Progression of atherosclerosis was 
reduced by 40% for minimal vessel diameter (p = 0.04), particu- 
larly in lesions <50% stenosis at baseline. There was a consistent 
although not statistically significant effect on mean diameter and 
percent diameter stenosis. There were also fewer new lesions in 
those assigned pravastatin (p _< 0.03). Myocardial infarction was 
reduced during active treatment (8 in the pravastatin group, 17 in 
the placebo group; log-rank test, p _< 0.05; 60% risk reduction), 
with the benefit beginning to emerge after 1 year. 
Conclusions. In patients with coronary artery disease and mild 
to moderate cholesterol elevations, pravastatin reduces progres- 
sion of coronary atherosclerosis and myocardial infarction. The 
time course of event reduction increases the potential for a 
relatively rapid decrease in the clinical manifestations of coronary 
artery disease with lipid lowering. 
(J Am Coil Cardiol 1995;26:1133-9) 
Reduction of total and low density lipoprotein (LDL) choles- 
terol levels has been shown to be effective in slowing angio- 
graphically assessed progression of coronary atherosclerotic 
plaque and improving clinical outcome in studies of patients 
with established coronary artery disease (2,3). Most of these 
trials have used diet alone or in conjunction with multiple drug 
regimens to reduce serum lipids in patients with relatively 
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severe hyperlipidemia (2-4). Despite evidence of a clinical 
benefit, many physicians do not prescribe lipid-lowering ther- 
apy for patients with established coronary artery disease (5). In 
part, the failure to more vigorously detect and treat hyperlip- 
idemia can be attributed to the need for adjustment of dosage, 
complexity and side effects of multiple drug regimens and the 
perceived modest benefit on clinical end points (i.e., cardio- 
vascular morbidity and mortality) with strategies before the 
availability of 3-hydroxy-3-methylglutaryl-coenzyme A reduc- 
tase inhibitors (reduetase inhibitors). In addition, although 
substantial evidence attests to a benefit of lipid-lowering 
therapy for patients with marked hyperlipidemia and coronary 
artery disease (2,4,6,7), data to support reating patients with 
more moderately elevated cholesterol levels have not been as 
convincing. The goal of the present study was to evaluate the 
effect of a treatment regimen easily adaptable to clinical 
practice (i.e., monotherapy with a reductase inhibitor, pravas- 
tatin, in conjunction with a fat-restricted iet versus a fat- 
restricted iet alone) on progression of coronary atherosclero- 
sis in patients with mild to moderate hypercholesterolemia and
coronary artery disease. 
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Methods  
The study design, baseline variables and recruitment expe- 
rience have previously been published (1). The study was a 
3-year, multicenter, randomized, double-blind, placebo- 
controlled trial of pravastatin (40 rag) monotherapy adminis- 
tered once daily. Inclusion criteria were 1) coronary artery 
disease videnced by one or more stcnoses ->50% or recent 
myocardial infarction or coronary angioplasty; and 2) average 
LDL cholesterol concentration ---130 mg/dl (3.36 mmolfliter) 
but <190 mg/dl (4.91 mmol/liter) and triglyceride levels 
-<350 mg/dl (3.95 mmoi/liter) despite adherence to a fat- 
restricted iet (American Heart Association phase I [8] or 
equivalent) for a minimum of 4 weeks. The protocol was 
approved by the institutional review board at each study site. 
Coronary angiography. The angiographic protocol and 
quantitative analysis methodology have previously been de- 
scribed (1,9). Matching end-diastolic frames for each of 10 
prospectively defined segments (1) were marked on each pair, 
masked for order and the films forwarded for digitization and 
quantitative analysis at the core angiography laboratory. In the 
analysis, if angioplasty or a bypass were performed in one of 
the three major vessels, that vessel was excluded. The left main 
stem was excluded in cases of mechanical intervention i  the 
left anterior descending or left circumflex coronary artery. 
Measurements of mean and minimal diameter and, if applica- 
ble, percent diameter stenosis were made for each evaluable 
segment. Segments with a total occlusion were assigned a value 
of 0 (for mean and minimal diameters) or 100% (for percent 
diameter stenosis), including segments with total obstruction at 
baseline that recanalized. No values were imputed for seg- 
ments distal to a total obstruction. Angiograms obtained >90 
days after randomization were eligible for inclusion in the 
analysis (1) as predefined in the protocol. The primary angio- 
graphic end point was mean coronary artery diameter (1). 
Clinical events. The following clinical outcomes were de- 
fined prospectively before study unblinding: fatal or nonfatal 
myocardial infarction; nonfatal infarction or coronary heart 
disease death; nonfatal infarction or death from any cause; and 
total clinical events (nonfatal myocardial infarction, nonfatal 
completed stroke, death, angioplasty or coronary bypass ur- 
gery). For cases of myocardial infarction, death and stroke, 
documentation was reviewed by an independent Clinical 
Events Adjudicating Committee.* Classification of myocardial 
infarction was based on criteria that incorporated the presence 
of ischemic hest pain, elevation in the cardiac reatine kinase 
(CK) isoenzyme fraction and evolution of electrocardiographic 
changes. Coronary heart disease and noncardiac deaths were 
documented from a death certificate, coroner's report or 
autopsy report, with supporting hospital records if available; 
the documentation was reviewed and the cause of death 
*Thomas J. Bigger, Jr., MD, Columbia University, New York, New York; 
Morrison Hodges, MD, Hennepin County Medical Center, Minneapolis, Min- 
nesota; Leon Resnekov, MD (deceased), University. of Chicago, Chicago, 
Illinois. 
classified by the adjudicating committee. Coronary angioplasty 
and bypass urgery were documented by hospital records. A 
prospectively defined subset analysis was performed for clinical 
events occurring during the period from >90 days after 
randomization to the end of the study, in parallel with the 
angiographic assessments. 
Lipid and lipoprotein levels. Plasma concentrations of 
total cholesterol, high density lipoprotein (HDL) cholesterol 
(separated by heparin-manganese chloride precipitation) and 
glycerol-blanked triglycerides were determined using auto- 
mated enzymatic methods (Miles-Technicon) at the Lipid 
Research Center, Washington University School of Medicine; 
LDL cholesterol was calculated using the Friedewalde for- 
mula. 
Statistical evaluation. Baseline characteristics of patients 
in the two treatment groups were compared by one-way 
analysis of variance (continuous variables) and chi-square tests 
(categoric variables). Quantitative angiographic outcome vari- 
ables, calculated as annual rates of progression averaged over 
all evaluable segments, were analyzed by analysis of covari- 
ance. Consistency of results across ites was assessed by testing 
a treatment-by-site nteraction term at the 10% significance 
level. Clinical events were analyzed by the Kaplan-Meier 
method and log-rank test. Patients lost to follow-up were 
treated as censored at the last visit. The association between 
on-trial plasma lipoproteins (average values of LDL choles- 
terol and LDI_flrlDL cholesterol ratio during the study) and 
progression of atherosclerosis was examined by correlation 
coefficients (Pearson's product-moment correlation and Spear- 
man's rank correlation) and linear regression analysis. Other 
risk factors such as age, gender and systolic blood pressure 
were examined in a stepwise selection procedure to determine 
a set of independent variables in predicting progression. To 
assess the association of time to clinical events with lipoprotein 
levels (posttreatment average), the log-rank test based on 
exponential scores was used. Effects of risk factors (as previ- 
ously stated) were also examined using the SAS PROC 
LIFETEST. The average lipid levels of follow-up visits were 
analyzed by analysis of covariance. All tests were two-sided. 
Results  
Patient disposition. Baseline demographic features are 
shown in Table 1. Evaluable follow-up angiography was ob- 
tained in 320 of the 408 patients randomized, including 56 of 
141 subjects who discontinued the study drug at some time 
during the trial. The most common reason for discontinuing 
the study medication was coronary artery bypass graft surgery 
(a study end point); 17 pravastatin-treated and 21 placebo- 
treated patients discontinued therapy for this reason. Other 
causes for discontinuing the study medication or lack of 
follow-up angiography were similar between treatment groups 
except for physician request, which was more common in the 
placebo group (n = 10 vs. 0 in the pravastatin group). Two 
patients in each group were discontinued for noncompliance 
with the protocol, as judged by the investigator. Mean (_+SD) 
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Table 1. Baseline Cardiovascular Risk Factors and Demographic 
and Angiographic Variables 
Pravastatin Placebo 
(n : 206) (n - 202) 
Male gender 70 76 
Current smoker 10 14 
Hypertension 47 44 
Family history of atherosclerosis 51 56 
Prior MI 4~ 41 
Prior angioplasW 55 55 
Prior corona~ artery bypass 3 6 
Medications 
Aspirin ~7 71 
Calcium blocker 67 63 
Beta-blocker 35 3t~ 
ACE inhibitor 7 ,~ 
Total no. of segments* 1,433 1,40(I 
% distribution of lesions 
-<15 338 34q 
16-30 449 433 
31-50 436 400 
51-75 132 141 
75-1110 24 15 
100 54 53 
Mean vessel diameter (mm)+ 2.58 (0511 2.6(I (0.50) 
Minimal vessel diameter (mm)+ 2.(13 (0,46) 2.07 (046) 
% diameter stenosM 29 (9.651 28 (0.96) 
*Includes all segments in 320 patients with evaluable follo~v-up angiography 
tExcluding vessels with bypass urgery, and angioplasty. Unless otherwise indi- 
cated, data presented are percent of patients or mean value (SD). ACE - 
angiotensin-converting enzyme; MI myocardial infarction, 
follow-up for patients randomized to the placebo and prava- 
statin groups was 826 _+ 373 and 884 _+ 348 days, respectively. 
The average dose of pravastatin was 39 mg daily. 
Lipid levels. There were significant and sustained ecreases 
in plasma levels of total (baseline 231 mg/dl [5.97 retool/liter]) and 
LDL cholesterol (baseline 164 mg/dl [4.24 retool/liter]) and 
triglycerides (baseline 166 mg/dl [1.87 retool/liter]) and an 
increase in HDL cholesterol (baseline 4l mg/dl ]1.06 mmol/ 
liter]) during pravastatin treatment compared with placebo. In 
the pravastatin group, the average percent changes from 
baseline were as follows: total cholesterol - 19%, LDL choles- 
terol -28%, HDL cholesterol +7% and triglycerides -8% (all 
p < 0.001 vs. placebo). In the placebo group, the correspond- 
ing changes were +2%, +1%, +2~;~ and +9%, respectively. 
Average compliance in patients taking the study drug (as 
assessed by pill counts) was 959 in both groups. 
Angiographic progression rates. Follow-up angiography 
was obtained in 320 patients. The total number of evaluable 
segments was 1,084 (mean 6.7/patient) and 1,035 (mean 6.6/ 
patient) in the pravastatin and placebo groups, respectively. 
Angiographic progression rates were reduced by 40% to 505~ 
among patients randomized to receive pravastatin compared 
with those receiving placebo. In the placebo group, mean and 
minimal diameters decreased by 0.04 and 0.05 ram/year, re- 
spectively. In the pravastatin group, the corresponding de- 
creases were 0.02 mm/year (p - 0.161 and 0.03 mm/year (p 
(t.I141. Percent diameter stenosis increased in the placebo group 
by 1.12%/year versus 0.69%/year in the pravastatin group (p = 
0.13). If total occlusions are excluded from the analysis, then 
for mean and minimal diameters and percent diameter steno- 
sis, p = 0.09, 0.02 and 0.05, respectively. Progression of 
atherosclerosis was found to be correlated with both on-trial 
average LDI, cholesterol and the ratio of LDL to HDL 
cholesterol. For the LDIJHDI, cholesterol ratio, the correla- 
tion coefficients were small but statistically significant for mean 
diameter (r - 0.12, 95% confidence interval [CI] -0.23 to 
-0.01) and minimal diameter (r - 0.15, 95% CI -0.25 to 
0.04). Correlation coefficients were similar for average on- 
trial I,DI, cholesterol alone. Inclusion of non-HDL cholesterol 
in the model did not affect the resnlt. Regression analysis 
indicates that every 22 mg/dl ((/50 retool/liter) increment in 
I,DL cholesterol results in 0.01 mm~year ofadditional narrow- 
ing in minimal umen diameter within the observed on-trial 
range of 70 to 218 mg/dl (2.02 to 5 84 retool/liter). Doubling 
the IDL cholesterol level from 10O mg/dl (2.59 mmol/liter) to 
200 mg/dl (5.17 retool/liter) increases the rate of progression of 
minimal diameter 3.5-fold. When competing risk factors (age, 
gender, systolic blood pressure) were examined for joint effects 
of covariates, LDL cholesterol remained the most important 
predictor for progression of coronary atberosclerosis. 
In a predefined subset analysis according to baseline lesion 
severity, the major effect of pravastatin was to inhibit anglo- 
graphic progression of coronary artery, disease in segments 
with lesions <50% diameter stenosis ~t baseline and to reduce 
new lesion formation (p -<- 0.03 vs. placebo) (Fig. 1). There 
were no statistically significant differences in progression rates 
in segments with baseline stenosis -'-:-50%. 
The distribution of patients with progression, regression, 
mixed progression/regression or o change for minimal diam- 
eter and percent diameter stenosis is shown in Table 2. 
Progression was defined as progression i  at least one segment 
and no evidence of regression. Regression was defined simi- 
larly. Results are given for the cutoff values defined at the 
beginning of the trial of 0.62 mm for minimal diameter and 
-->--16% for percent diameter stenosis and also for the cutoff 
points of 0.40 mm and >-15% described by other investigators 
(10,11). For percent diameter stenosis, progression defined by 
an increase >-15% has been shown to be related to future risk 
of coronary heart disease death (12). The results indicate fewer 
patients with progression i  the pravastatin-treated group but 
similar rates of regression. 
Clinical events. Clinical cardiovascular event rates were 
significantly reduced among patients randomized to receive 
pravastatin (Table 3), primarily through a reduction in the 
event rate for myocardial infarction (fatal and nonfatal: log- 
rank, p ~ 0.05; risk reduction 60%). For events occurring 
during the period from 90 days after randomization to the end 
of the study, p -<- 0.01 (risk reduction 74%). As shown in Figure 
2, the curves for myocardial infarction in the pravastatin and 
placebo groups begin to diverge after the first year. There were 
10 total deaths, 6(5 after 90 days on trial) in the placebo group 
and 4 (all after 911 days) in the pravastatin group. When risk 
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Figure 1. Effect of pravastatin (solid columns, n = 163) 
on angiographic progression rates in lesions with <50% 
stenosis at baseline and on new lesion formation versus 
placebo (open columns, n = 157). The major effect of 
pravastatin was to reduce progression in lesions <50%, as 
shown by the changes in minimal diameter and percent 
diameter stenosis. Fewer patients reated with pravastatin 
developed new lesions, defined as an increase by at least 
16% diameter stenosis in a segment with a baseline 
stenosis <16%. Results are shown as mean change (col- 
umns) with standard error (vertical bars). A negative 
number for mean and minimal diameters and a positive 
number for percent diameter stenosis ndicate progres- 
sion. *p -< 0.03. For mean diameter, p = 0.07 for 
pravastatin versus placebo. 
factors (LDL cholesterol, LDL/HDL cholesterol ratxo, age, 
gender and systolic blood pressure) were examined for joint 
effects of covariates, only average on-trial LDL cholesterol was 
identified to be associated with time to infarction, although it
was only marginally significant (p = 0.09). The relation was 
negative, suggesting that lower LDL cholesterol levels are 
associated with a longer infarction-free p riod. 
Clinical events were also evaluated in special subgroups of 
interest where there is current debate about the benefits of 
lipid-lowering therapy: the elderly (n = 94), patients with 
baseline LDL cholesterol <160 mg/dl (4.13 mmol/liter, n = 
177) and women (n = 92). There was a trend in favor of 
pravastatin i  each of these groups, and for myocardial infarc- 
tion the difference was statistically significant among women. 
For those ->65 years old, among the 52 patients receiving 
placebo, there were 17 events in 11 patients (6 myocardial 
infarctions [log-rank, p = 0.21 vs. pravastatin], 1 sudden death, 
1 noncardiac death, 2 strokes and 1 angioplasty and 6 bypass 
surgery procedures). Among the 42 patients receiving pravas- 
tatin, there were eight events in eight patients (two myocardial 
infarctions, one noncardiac death and two angioplasty and 
three bypass urgery procedures). In the subgroup with base- 
line LDL cholesterol < 160 mg/dl (4.13 retool/liter), among the 
92 patients receiving placebo there were 33 events in 23 
patients (9 myocardial infarctions [log-rank, p = 0.09 vs. 
pravastatin], 1 sudden death, 1 noncardiac death, 1 noncardiac 
death, 1 stroke and 12 angioplasW and 9 bypass surgery 
procedures). In the 85 patients receiving pravastatin, there 
were 25 events in 21 patients (3 myocardial infarctions, 1 
sudden death and 9 angioplasty and 12 bypass urgery proce- 
dures). For the 92 women, among the 48 patients receiving 
placebo there were 12 events in 5 patients (4 myocardial 
infarctions [log-rank, p = 0.04 vs. pravastatin], 1 noncardiac 
death, 1 stroke and 3 angioplasty and 3 bypass urgery proce- 
dures). Among the 44 women receiving pravastatin, there were 
five events in five patients (two angioplasty and three bypass 
surgery procedures). 
Drug safety. Therapy with pravastatin was well tolerated. 
Adverse events occurred with similar frequency inboth groups 
except for dyspepsia/heartburn, which occurred more fre- 
quently in the pravastatin group (17% of patients vs. 9% in the 
placebo group, p -< 0.05). The syndrome of drug-induced 
myopathy (myalgia nd increase in CK levels to >10 times the 
upper limit of normal) was not observed in any patient. Mean 
values for aspartate aminotransferase nd alanine aminotrans- 
ferase were slightly (2 to 4 IU/liter) elevated from baseline in 
the pravastatin group at most annual follow-up visits (p -< 0.05 
vs. placebo), although no patient receiving pravastatin was 
discontinued for an increased transaminase level. 
Discuss ion 
As predicted from previous studies (6,7,11,13-18), the 
decrease in LDL cholesterol and increase in HDL cholesterol 
with pravastatin the present study of patients with mild to 
moderate hyperlipidemia were associated with a reduction in 
Table 2. Proportion of Patients With Angiographic Progression and Regression 
Percent Stenosis 
Cutoff Value -> 15% Cutoff Value ~16% 
Minimal Vessel Diameter 
Cutoff Value ->0.40 mm Cutoff Value -->-0.62 mm 
Pravastatin Placebo Pravastatin Placebo Pravastatin Placebo Pravastatin Placebo 
(n = 163) (n = 157) (n = 163) (n = 157) (n = 163) (n = 157) (n = 163) (n = 157) 
Progression 42 (26)* 59 (38) 42 (26)t 55 (35) 60 (37)* 79 (50) 46 (28) 58 (37) 
Regression 22 (14) 22 (14) 19 (12) 19 (12) 34 (21) 24 (15) 17 (10) 13 (8) 
Mixed progression/regression 20 (12) 21 (13) 15 (9) 19 (12) 26 (16) 30 (19) 7 (4) 9 (6) 
No change 79 (48)* 55 (35) 87 (53)* 64 (41) 43 (26)* 24 (15) 93 (57) 77 (49) 
*p -< 0.03. tp = 0.07. Data presented are number (%) of patients. 
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Table 3. Effects of Pravastatin on Cardiovascular Events 
All Events After Randomization Events After 90 Days 
Pravastatin Placebo Pravastatin Placebo 
(n 206) (n - 202) (n - 206) (n 202) 
MI (nonfatal/fatal) 8 (7/1)* 17 (16/I) 5 (4/1)t 17 (16/1) 
Other cardiac death:~ 2 2 2 1 
Stroke 0 2 0 2 
Bypass urgery 20 23 15 20 
Coronary angioplasty§ 25 37 20 29 
Total cardiovascular 55 81 42 69 
events 
Noncardiovascular deaths 1 3 1 3 
*p <- 0.05, +p < (I.01 versus placebo. :~lncludes three sudden deaths (two in placebo group, one in pravastatin group) 
and one resuscitated cardiac arrest (pravastatin group). §Includes more than one event/patient. Data presented are 
number of events. MI - myocardial nfarction. 
angiographically assessed minimal coronary artery diameter 
relative to placebo. These effects were most marked in mild 
lesions (<50% diameter stenosis at baseline) and in preventing 
new lesion formation (Fig. 1). Progression and rupture of mild 
coronary artery lesions and new lesion formation are now 
recognized to be important in the pathogcnesis of myocardial 
infarction (19-22). 
Time course of clinical event reduction. What was not 
predicted on the basis of previous tudies of LDL cholesterol 
reduction before availability of the reductase inhibitors was the 
time course of the reduction in myocardial infarction event 
rate in the current study. Law et al. (3), in a recta-analysis of
older secondary prevention studies, found only a 7% reduction 
in ischemic events during the first 2 years of lipid-lowering 
therapy on the basis of a 10% reduction in total cholesterol. 
However, in the present study close to a 50% reduction in 
events (infarction) was observed at 2 years for a 19% decrease 
in total cholesterol. Most of the reduction in recurrent isch- 
emic events in the meta-analysis of Law et al. (3) occurs during 
the second to fourth years of somewhat modest reductions in 
lipid levels. The relatively early reduction in ischemic events 
observed in the present study has also been seen in other 
recent monotherapy trials with pravastatin--the Pravastatin 
Multinational Study in Cardiac Risk Patients (23), the Prava- 
statin, Lipids, and Atherosclerosis in the Carotid Arteries 
(PLAC II) trial (24) and the Scandinavian Simvastatin Survival 
Study (4). The explanation for the relatively early reduction in 
ischemic events with these reductase inhibitors when used as 
monotherapy is unclear. The degree of LDL cholesterol re- 
duction seen in those studies is similar to that found in trials 
such as the Program on the Surgical Control of the Hyperlip- 
idcmias study (7), in which a lag phase of up to 3 years 
occurred before an effect on events began. 
Potential mechanism for clinical event reduction. Plaque 
stabilization affecting mild and new lesions, which is thought o 
result from a decrease in the lipid content of plaques conse- 
quent to sustained reductions in LDL cholesterol is probably 
of importance in the effectiveness of various lipid-lowering 
regimens in decreasing ischemic events. However, a reduction 
in LDL and total cholesterol is also associated with normal- 
ization of endothelial dysfunction, which occurs in the pres- 
ence of hypercholesterolemia w th or without manifest coro- 
nary artery disease (25-28). Cholesterol reduction with both 
cholestyramine (29) and the reductase inhibitors (27,28,30) has 
been shown to reverse ndothelial dysfunction i  patients with 
coronary artery disease within 6 months (27,29,30). This 
Figure 2. Effect of pravastatin on rate of nonfatal 
and fatal myocardial infarction from time of ran- 
domization: Kaplan-Meier estimate. An effect on 
the event rate begins to emerge after 1 year of 
treatment. 
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mechanism ay also directly modify the propensity to plaque 
rupture, platelet deposition after plaque rupture, thrombosis 
and progression of coronary atherosclerosis. A reduction in 
LDL cholesterol might also reduce monocyte migration into 
the arterial wall and hence the tendency for plaque rupture 
(31). 
Another possibility that could contribute to the relatively 
early reduction in myocardial infarction by pravastatin is its 
effect on platelet-induced thrombosis (32). I_am et al. (33) 
pointed out that patients with enhanced thrombin-induced 
platelet aggregation have a more rapid angiographic progres- 
sion of coronary artery disease as well as a significantly 
increased incidence of ischemic events. 
Many clinicians have been hesitant to apply lipid-lowering 
or dietary therapies because of the perceived long delay in 
their effectiveness. This perception has largely been fostered by 
the observation that induction of morphologic hanges in the 
coronary artery tree takes a long time. However, data showing 
a relatively early reduction in symptoms (5,6), myocardial 
infarction and ischemic events (23,24) as well as total mortality 
(4) with reductase inhibitors or a Mediterranean diet (34) 
suggest that these types of interventions are appropriate for 
early treatment of asymptomatic aswell as symptomatic pa- 
tients with ischemic heart disease. 
There is a need to determine whether afurther eduction i  
LDL cholesterol beyond that achieved in the current study or 
the Scandinavian Simvastatin Survival Study (4) would be 
more effective. It should be pointed out that only 14% of the 
pravastatin-treated patients in the present study reached the 
National Cholesterol Education Program (NCEP) Adult 
Treatment Panel II (35) goal of a reduction i  LDL cholesterol 
to <100 mg/dl (2.59 mmol/liter). Multiple drug regimens as 
used in the Familial Atherosclerosis Treatment Study (FATS) 
(6) and other angiographic trials (14,15) have achieved a 
greater reduction in LDL cholesterol and progression of 
coronary artery disease, along with evidence of coronary artery 
disease regression. In addition, an early reduction in ischemic 
events was noted in the FATS (6), although there was no effect 
on myocardial infarction. It should be noted that the baseline 
LDL cholesterol values in the multiple-drug therapy studies 
were also considerably higher than those in the present trial. 
Further studies are required to determine whether multiple- 
drug regimens, with the attendant greater eductions in LDL 
cholesterol, result in greater and earlier decreases in events 
compared with pravastatin monotherapy as used in the present 
study. 
Conclusions. There is increasing evidence for a benefit of 
lipid-reducing drugs and dietary strategies for the secondary 
prevention of ischemic heart disease (2-4). Patients with 
known coronary artery disease and elevated serum LDL 
cholesterol levels >130 mg/dl (3.36 mmol/liter) should be 
placed on an effective diet and drug therapy, preferably a 
reductase inhibitor. A Mediterranean diet (34) and life-style 
changes (36) might be more desirable than pharmacologic 
lipid-lowering therapy alone. However, for those patients who 
cannot adhere to or respond slowly or inadequately to such 
diet or life-style changes, therapy with a reductase inhibitor 
should be considered. 
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